These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10136058)

  • 21. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
    Birch S; Gafni A
    J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stochastic league tables: communicating cost-effectiveness results to decision-makers.
    Hutubessy RC; Baltussen RM; Evans DB; Barendregt JJ; Murray CJ
    Health Econ; 2001 Jul; 10(5):473-7. PubMed ID: 11466807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The future of health economic modeling: have we gone too far or not far enough?
    Fendrick AM
    Value Health; 2006; 9(3):179-80. PubMed ID: 16689711
    [No Abstract]   [Full Text] [Related]  

  • 24. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dollar is a dollar is a dollar--or is it?
    Brouwer WB; van Exel NJ; Baltussen RM; Rutten FF
    Value Health; 2006; 9(5):341-7. PubMed ID: 16961552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling programme costs in economic evaluation.
    Fenn P; McGuire A; Backhouse M; Jones D
    J Health Econ; 1996 Feb; 15(1):115-25. PubMed ID: 10157425
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of age on cost-effectiveness ratios and its control in decision making.
    Baltussen R; Leidl R; Ament A
    Health Econ; 1996; 5(3):227-39. PubMed ID: 8817297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and cost-benefit analysis of health services: the methodology and its application.
    Griffiths A
    Health Policy; 1988; 9(3):251-65. PubMed ID: 10312550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of economic appraisal in Denmark.
    Alban A
    Soc Sci Med; 1994 Jun; 38(12):1647-52. PubMed ID: 8047923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.
    Birch S; Gafni A
    J Health Econ; 1993 Dec; 12(4):469-76. PubMed ID: 10131757
    [No Abstract]   [Full Text] [Related]  

  • 32. A note on the depreciation of the societal perspective in economic evaluation of health care.
    Johannesson M
    Health Policy; 1995 Jul; 33(1):59-66. PubMed ID: 10143700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
    Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
    Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Problems in interpreting cost effectiveness in clinical trials. Experimental versus implementation costs.
    De Nino LA; Mulrow CD; Gerety MB; Averyt EC
    Online J Curr Clin Trials; 1993 Apr; Doc No 44():[4864 words; 42 paragraphs]. PubMed ID: 8306003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of cancer treatments: methodological and practical issues.
    Uyl-de Groot CA; Touw CR
    Anticancer Drugs; 1998 Nov; 9(10):835-41. PubMed ID: 9890694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness. How should it be determined?
    Beaves RG; Joseph H; Rohrer JE; Zeitler RR
    Eval Health Prof; 1988 Jun; 11(2):213-30. PubMed ID: 10312609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness challenge: is it worth it?
    Knapp M
    Alzheimers Res Ther; 2015 Jan; 7(1):10. PubMed ID: 27391601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit analyses in the health-care literature: don't judge a study by its label.
    Zarnke KB; Levine MA; O'Brien BJ
    J Clin Epidemiol; 1997 Jul; 50(7):813-22. PubMed ID: 9253393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QALYs (quality-adjusted life-years) versus HYEs (healthy years equivalents).
    Culyer AJ; Wagstaff A
    J Health Econ; 1993 Oct; 12(3):311-23. PubMed ID: 10129839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.